Evaxion Biotech has completed subject dosing in the Phase II trial of its personalised peptide-based cancer vaccine, EVX-01, for the treatment of advanced melanoma, also referred to as skin cancer.
Clinical Trials
Neoadjuvant Pembrolizumab Appears Tolerable in Stage IIIB-D Melanoma
The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin,